Loading...
 
Translate Register Log In Login with facebookLogin and Register

PCOS treated by a combination of Vitamin D and Omega-3 – RCT Oct 2018

The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome

Journal of Affective Disorders, Vol 238, 1 Oct 2018, Pages 32-38, https://doi.org/10.1016/j.jad.2018.05.027
Mehri Jamiliana Mansooreh Samimib Naghmeh Mirhosseinic Faraneh Afshar Ebrahimib Esmat Aghadavodd Rezavan Talaeee Sadegh Jafarnejadd Shahrzad Hashemi Dizaji fZatollahAsemid

VitaminDWiki

Starting to see Vitamin D combinations used for treatment in the Summer of 2018
This RCT used 50,000 IU vitamin D every 2 weeks plus 2000 mg/day Omega-3



Items in both categories Depression and Omega-3 are listed here:


Items in both categories Pregnancy and Omega-3 are listed here:

Accepted manuscript PDF is available free at Sci-Hub

Highlights

  • This study has evaluated the effects of omega-3 plus vitamin D intake in PCOS women.
  • Co-supplementation in PCOS women had beneficial effects on mental health.
  • Co-supplementation in PCOS women improved metabolic profiles.

Objective
The aim of this study was to evaluate the effect of the co-administration of vitamin D and omega-3 fatty acid on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome (PCOS).

Methods
This randomized, double-blinded, placebo-controlled clinical trial was conducted on 60 subjects, aged 18–40 years old with PCOS. Subjects were randomly allocated to take either 50,000 IU vitamin D every 2 weeks plus 2000 mg/day omega-3 fatty acid from fish oil (n = 30) or placebo (n = 30) for 12 weeks. Gene expression analysis of inflammatory cytokines was conducted on peripheral blood mononuclear cells (PBMCs) of PCOS women using RT-PCR method.

Results
Vitamin D and omega -3 fatty acid co-supplementation significantly decreased serum total testosterone levels (−0.2 ± 0.5 vs. + 0.1 ± 0.4 ng/mL, P = 0.02) compared with the placebo. In addition, vitamin D and omega-3 fatty acid co-supplementation resulted in a
significant improvement in

  • beck depression inventory (−1.4 ± 1.6 vs. −0.5 ± 0.6, P = 0.01),
  • general health questionnaire scores (−4.5 ± 4.3 vs. −1.9 ± 2.3, P = 0.005) and
  • depression anxiety and stress scale scores (−5.0 ± 5.1 vs. −2.3 ± 3.5, P = 0.01)

compared with the placebo.
Additionally, vitamin D and omega-3 fatty acid co-administration significantly decreased

  • serum high-sensitivity C-reactive protein (hs-CRP) (−1.2 ± 1.9 vs. + 0.1 ± 0.7 mg/L, P = 0.001) and
  • malondialdehyde (MDA) levels (−0.4 ± 0.4 vs. + 0.2 ± 0.6 µmol/L, P < 0.001), and

significantly increased

  • plasma total antioxidant capacity (TAC) levels (+ 114.6 ± 122.2 vs. -2.4 ± 168.2 mmol/L, P = 0.003)

compared with the placebo. Results of RT-PCR demonstrated that vitamin D and omega-3 fatty acid co-supplementation significantly downregulated gene expression of interleukin-1 (IL-1) (P = 0.03), and upregulated vascular endothelial growth factor (VEGF) (P = 0.004) in PBMCs of subjects with PCOS, when compared with placebo.

Conclusions: Overall, the co-administration of vitamin D and omega-3 fatty acid for 12 weeks had beneficial effects on mental health parameters, serum total testosterone, hs-CRP, plasma TAC and MDA levels, and gene expression of IL-1 and VEGF among women with PCOS.

Created by admin. Last Modification: Wednesday July 11, 2018 23:55:53 UTC by admin. (Version 5)
See any problem with this page? Report it (FINALLY WORKS)